Cargando…
Proliferative Glomerulonephritis with Monoclonal IgG Deposits and Refractory Ascites: Successful Treatment with Rituximab and Cell-free and Concentrated Ascites Reinfusion Therapy
A 49-year-old woman presented with nephrotic-range proteinuria, microhematuria, and moderate renal dysfunction. Diuretic-resistant refractory ascites associated with nephrotic syndrome were observed. Based on the histopathological findings, the patient was diagnosed with proliferative glomerulonephr...
Autores principales: | Takami, Norito, Inoue, Masatoshi, Kobayashi, Yoichi, Sugiyama, Yutaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449609/ https://www.ncbi.nlm.nih.gov/pubmed/35110486 http://dx.doi.org/10.2169/internalmedicine.8799-21 |
Ejemplares similares
-
Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor
por: Miyamoto, Yasunori, et al.
Publicado: (2021) -
Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results
por: Hanafusa, Norio, et al.
Publicado: (2017) -
Reinfusion of ascites during hemodialysis as a treatment of massive refractory ascites and acute renal failure
por: Hsu, Ta-Wei, et al.
Publicado: (2011) -
Ascites reinfusion dialysis of refractory ascites as a bridge to kidney and liver transplantation in a patient on hemodialysis
por: Chang, Kyung Yoon, et al.
Publicado: (2017) -
Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan
por: Iwasa, Motoh, et al.
Publicado: (2019)